rethinkPeptides Search
Menu
Study breakdown

Progress in CRF-1 Antagonist Drug Development for Anxiety and Depression

evidence
The takeaway

Updated review of CRF-1 receptor antagonist development for anxiety and depression, covering new compounds, clinical trial results, and reasons for mixed success — the continuing quest for stress peptide drugs.

Key finding

Updated review of CRF-1 receptor antagonist development for anxiety and depression, covering new compounds, clinical trial results, and reasons for mi

What the researchers found

Updated review of CRF-1 receptor antagonist development for anxiety and depression, covering new compounds, clinical trial results, and reasons for mixed success — the continuing quest for stress peptide drugs.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2010.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
Progress in CRF-1 Antagonist Drug Development for Anxiety and Depression
What was found?
Updated review of CRF-1 receptor antagonist development for anxiety and depression, covering new compounds, clinical trial results, and reasons for mixed success — the continuing quest for stress peptide drugs.

Read the original research

Progress in corticotropin-releasing factor-1 antagonist development.

Drug discovery today, 15(9-10), 371-83

Citation

Zorrilla, Eric P; Koob, George F. (2010). Progress in corticotropin-releasing factor-1 antagonist development.. Drug discovery today, 15(9-10), 371-83. https://doi.org/10.1016/j.drudis.2010.02.011